|
|
 |
History
Date |
Event |
April, 2003 |
Company Founded as Maryland Biotherapeutics (MBTI), Robert Ting, Ph.D., named President |
March, 2004 |
Executed license with UMBI for Transition-State Vaccine (TSV) and Genetic Adjuvant technology |
May, 2004 |
MBTI renamed Profectus BioSciences, Inc. |
November, 2004 |
$2.3M in seed money raised (convertible debt) |
January, 2005 |
Operations commenced |
April, 2005 |
Option agreement signed between Profectus BioSciences and Wyeth to evaluate TSV technology ($5.3 million) |
July, 2005 |
Executed license with UMB and UMBI for AIM Therapy Technology |
August, 2005 |
First NIH R01 grant awarded for TSV technology ($350,000) |
September, 2005 |
Profectus names Joe Berardino as CEO. |
November, 2005 |
Material Transfer Agreement signed with Leading Veterinary Company for Genetic Adjuvant technology for veterinary applications e.g. Avian Flu, Rabies, etc. |
January, 2006 |
CRADA signed with NCI for Antiviral MAbs |
March, 2006 |
Profectus honored with Incubator Company of the Year Award (MD) |
April, 2006 |
$5.3M Series A round (including conversion of convertible debt) |
October, 2006 |
First Maryland Industrial Partnership (MIPS) grant awarded ($200,000) for AIM Therapy |
January, 2007 |
Second MIPS grant awarded ($100,000) for Genetic Adjuvant technology |
March, 2007 |
Profectus honored as the Best Academic/ Industry Collaboration Award by the Greater Baltimore Committee. |
June, 2007 |
$3M Private Placement of Convertible Notes and Warrants |
June, 2007 |
First NIH Phase 1 SBIR grant awarded for Genetic Adjuvant technology ($300,000) |
July, 2007 |
Second NIH Phase 1 SBIR grant awarded for AIM Therapy technology ($200,000) |
January, 2008 |
Profectus names Shawn Patrick O’Brien as President, CEO. |
June, 2008 |
Third NIH Phase 1 SBIR grant awarded for Genetic Adjuvant technology ($300,000) |
June, 2008 |
William Haseltine, Ph.D. joins Board of Directors |
July, 2008 |
Fourth NIH Phase 1 SBIR grant awarded for AIM Therapy technology ($200,000) |
August, 2008 |
$4.5M Series B round completed, Profectus moves to 6411 Beckley Street, Baltimore, MD |
August, 2008 |
Thomas Paese, Esq. joins Board of Directors, Jeffrey Stello joins Profectus as Chief Financial Officer |
September, 2008 |
NIH funded HIV Vaccine Design and Development Team (HVDDT) contract awarded for “Therapeutic Immunization Against HIV with Adjuvant-enhanced DNA and Multi-epitope Peptide Vaccines” ($17,572,224) |
September, 2008 |
NIH funded HIV Vaccine Design and Development Team (HVDDT) contract awarded for “HIV-1 Vaccine Candidates Delivered by VSV Vectors” ($4,019,483) |
October, 2008 |
John Eldridge, Ph.D. joins Profectus as Chief Scientific Officer, Vaccines |
November, 2008 |
Profectus executes an Assignment and License Agreement with Wyeth for vaccines against HIV, HCV, HPV, HSV, and Malaria |
| December, 2008 |
Profectus receives “People’s Choice” Award at the 2008 Bio-Life-Tech Conference in Baltimore, MD |
| May, 2009 |
Tech Council of Maryland selects Profectus as a finalist for Emerging Company of the Year, 2009 |
| June, 2009 |
US Commerce Association selects Profectus for Best of Baltimore Award for Commercial Biotechnical Research Company of the Year, 2009 |
| July, 2009 |
$5M in Series C Venture funding completed |
| July, 2009 |
Profectus secures $105K grant from Empire State Development to expand operations to Westchester County, NY |
| August, 2009 |
Profectus establishes research collaboration agreement with PATH Malaria Vaccine Initiative (MVI) to evaluate rVSV vector technology |
| December, 2009 |
Profectus NY operations moves into 777 Old Saw Mill River Road, Tarrytown, NY |
| January, 2010 |
Thomas Pease is appointed Executive Chairman |
| January, 2010 |
Frost & Sullivan awards Profectus 2010 Global Entrepreneurial Company of the Year in Vaccines |
| January, 2010 |
Baltimore SmartCEO recognizes Profectus as one of the 50 fastest-growing companies in the Greater Baltimore area |
| April, 2010 |
NIH awards 2 Phase 1 SBIRs totaling $495,572 to support development of novel Genetic Adjuvants |
| April, 2010 |
NIH awards Phase 2 SBIR of $2,447,584 to evaluate CTA1 adjuvant technology as a component of an HIV vaccine. |
| June, 2010 |
NIH supplements HVDDT contract for $2,740,852 to manufacture new rVSV based HIV vaccine |
| July, 2010 |
NIH awards Fast Track SBIR for $3,161,379 to develop the Transition State HIV Vaccine |
| July, 2010 |
NIH awards R56 to support development of antiviral MAbs licensed from NCI ($625,704) |
| November, 2010 |
HIV Vaccine Trials Network announces data showing inclusion of Profectus Genevax pIL-12 improves response rate of electroporated HIV pDNA vaccine to 91% |
|
 |
|
